Stigma‐related barriers to medical cannabis as harm reduction for substance use disorder: Obstacles and opportunities for improvement

Abstract

Emerging evidence on substituting cannabis for more harmful drugs has led to cannabis becoming a novel harm‐reduction strategy for combating the current drug poisoning crisis. However, the authorization of medical cannabis as part of a harm‐reduction approach and recovery strategy has significant implementation barriers rooted in longstanding stigma towards cannabis. Through a multi‐discipline collaboration of Canadian clinicians and academic researchers, we highlighted stigma barriers and opportunities to address these barriers to elicit improved delivery of medical cannabis as a harm‐reduction therapy within existing therapeutic frameworks. Evidence from existing literature and real‐world experiences converged on three key themes related to stigma barriers: (1) Lack of medical cannabis education within the healthcare community, (2) lack of consensus and coordination among harm‐reduction services and (3) access to medical cannabis. We highlight potential solutions to these issues, including improved healthcare education, better coordination between care teams and suggestions for improving access. Through this discussion, we hope to contribute to reducing the stigma around using medical cannabis as a harm‐reduction strategy for individuals with a substance use disorder and consider new perspectives in policy development surrounding recovery services.